CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation announced today that it has been awarded a grant by the National Institute of Allergy and Infectious Diseases (NIAID) to fund the development of a recombinant vaccine for the prevention of dengue, a disease that kills an estimated 25,000 people annually. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.
